Paysign, Inc. Appoints Jose Garcia as Executive Vice President, Life Science Solutions

September 22, 2025 at 08:05 AM EDT

Garcia Tapped to Lead Strategy for Company’s Life Science Solutions

Paysign, Inc. (NASDAQ: PAYS), a leading provider of patient affordability programs, donor compensation solutions, engagement and management software platforms and integrated payment processing for the life sciences industries, today announced that it has appointed Jose Garcia as Executive Vice President, Life Science Solutions.

In his new role at Paysign, Mr. Garcia will implement and execute the market strategy for the company’s comprehensive suite of engagement and management solutions targeting the life sciences industries. With more than two decades of executive experience in life sciences services, Mr. Garcia is a seasoned leader with deep expertise in sales, marketing, and strategic relationship development. Prior to joining Paysign, he served as Vice President, Client Relationships at QualTex Laboratories, where he was instrumental in strengthening client partnerships in the blood and plasma collection industries as well as the human cell and tissue product (HCT/P) industry, driving brand visibility. Prior to that, he held the role of Vice President of Sales at two BioBridge Global companies, QualTex and GenCure, where he developed strategies that expanded the company’s footprint in the life sciences sector. His full professional background can be found on his LinkedIn profile.

“Jose is a proven leader with deep expertise in the plasma collection industry as well as the broader life sciences industry. His success in sales and client engagement makes him the perfect fit to spearhead the commercialization of our engagement and management software platforms,” said Mark Newcomer, President and CEO of Paysign. “His vision and experience will be invaluable as we continue to expand our presence in the life sciences space.”

“I am honored to join Paysign at such a pivotal time,” said Garcia. “I look forward to contributing to the company’s continued growth and innovation in serving the blood, plasma, and broader life sciences industries.”

About Paysign

Paysign, Inc. (NASDAQ: PAYS) operates at the intersection of fintech and healthcare, integrating advanced payment processing and program management with tailored technologies for the plasma, pharmaceutical and life sciences industries. Their breakthrough patient affordability solutions ensure patients receive the financial assistance they need to adhere to prescribed therapies by mitigating the effects of copay accumulators and maximizers. Paysign specializes in blood and plasma donor compensation programs, as well as comprehensive engagement and management platforms optimized for life sciences. Paysign’s proprietary processing architecture supports physical, virtual, mobile and bank-based payments with real-time transaction intelligence, enabling efficient, compliant and scalable program delivery. Through advanced reporting, analytics and in-house 24/7 bilingual customer support, Paysign delivers measurable value, exceptional service and a superior experience for donors, patients, healthcare providers, pharmaceutical manufacturers and program sponsors across their growing fintech healthcare ecosystem. The company is committed to improving efficiencies, reducing costs, streamlining communications, increasing program performance and providing actionable insights to those they serve.

Forward-Looking Statements

Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the companies, are forward-looking statements that involve risks and uncertainties. There is no assurance that such statements will prove to be accurate, and actual results and future events could differ materially. Paysign undertakes no obligation to publicly update or revise any statements in this release, whether as a result of new information, future events or otherwise.